These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37848754)

  • 1. Role of Modeling and Simulation in Preclinical and Clinical Long-Acting Injectable Drug Development.
    Siemons M; Schroyen B; Darville N; Goyal N
    AAPS J; 2023 Oct; 25(6):99. PubMed ID: 37848754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products.
    Gomeni R; Bressolle-Gomeni F
    J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):89-96. PubMed ID: 36484885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group.
    Bauer A; Berben P; Chakravarthi SS; Chattorraj S; Garg A; Gourdon B; Heimbach T; Huang Y; Morrison C; Mundhra D; Palaparthy R; Saha P; Siemons M; Shaik NA; Shi Y; Shum S; Thakral NK; Urva S; Vargo R; Koganti VR; Barrett SE
    Pharm Res; 2023 Jul; 40(7):1601-1631. PubMed ID: 36811809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 5. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of in vitro-in vivo correlations for long-acting injectable suspensions.
    Bao Q; Wang X; Wan B; Zou Y; Wang Y; Burgess DJ
    Int J Pharm; 2023 Mar; 634():122642. PubMed ID: 36709013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
    Darville N; van Heerden M; Mariën D; De Meulder M; Rossenu S; Vermeulen A; Vynckier A; De Jonghe S; Sterkens P; Annaert P; Van den Mooter G
    J Control Release; 2016 May; 230():95-108. PubMed ID: 27067365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
    Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
    CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.
    Chen WY; Lin SK
    J Clin Psychopharmacol; 2016 Oct; 36(5):492-5. PubMed ID: 27580495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Informed Drug Development for Long-Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium.
    Sharan S; Fang L; Lukacova V; Chen X; Hooker AC; Karlsson MO
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):220-228. PubMed ID: 33624456
    [No Abstract]   [Full Text] [Related]  

  • 11. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
    Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
    J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations.
    Schoretsanitis G; Meyer JM; Conca A; Hiemke C
    Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):189-202. PubMed ID: 37259573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
    Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
    J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region.
    Tang CT; Chua EC; Chew QH; He YL; Si TM; Chiu HF; Xiang YT; Kato TA; Kanba S; Shinfuku N; Lee MS; Park SC; Park YC; Chong MY; Lin SK; Yang SY; Tripathi A; Avasthi A; Grover S; Kallivayalil RA; Udomratn P; Chee KY; Tanra AJ; Rabbani MG; Javed A; Kathiarachchi S; Waas D; Myint WA; Sartorius N; Tran VC; Nguyen KV; Tan CH; Baldessarini RJ; Sim K
    Asia Pac Psychiatry; 2020 Dec; 12(4):e12393. PubMed ID: 32468725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial.
    Kane JM; Schooler NR; Marcy P; Achtyes ED; Correll CU; Robinson DG
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 31050233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.